BUZZ - Arbutus shares rise after FDA lifts clinical trial hold on an experimental hepatitis B drug

October 22 - ** Arbutus Biopharma (ABUS.O) shares rose 5.2% in pre-market trading to $4.39

** The company stated (link) that the U.S. Food and Drug Administration (FDA) has notified it that the clinical hold on its experimental drug AB-101 has been lifted, allowing clinical development to continue in the United States

** Arbutus is evaluating next steps for the development of AB-101, an oral PD-L1 inhibitor currently being studied in patients with chronic hepatitis B

** As of the close of the previous trading day, the stock had fallen 13% so far this year

(To assist non-native English speakers, Reuters provides automated translations of its reports in several other languages. Because automated translation may contain errors or may not convey the intended meaning, Reuters does not guarantee the accuracy of the automated translation. This is provided solely for the convenience of readers. Reuters accepts no liability for any loss or damage arising from use of the automated translation feature.)